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Background: Quality of life (QoL) is considered an important outcome in health research. It can be rated by the
patient, or by an external assessor. We wished to identify the predictors of any discrepancies between these two
approaches in people with schizophrenia.
Methods: Patients with DSM schizophrenia and related disorders (N = 80) completed both patient-rated (Lancashire
Quality of Life Profile; LQOLP) and assessor-rated (Heinrich’s Quality of Life Scale; QLS) measures of QoL.
Results: Patient-rated (LQOLP) and assessor-rated (QLS) measures showed a modest correlation (r = 0.38). In a regression
analysis, independent predictors of subjectively-rated QoL being higher than objectively-assessed QoL in the same
patient, were low insight score (BIS), negative symptoms (PANSS), absence of depression (CDSS), and less positive
attitude toward prescribed treatment (DAI).
Conclusions: In people with schizophrenia, scores on objectively- and subjectively-rated measures of quality of life can
differ markedly. When comparing subjective to objective assessments, patients with depressive symptoms will value
their QoL lower, and those with low insight will value their QoL higher. This has important implications for the utility
and interpretation of QoL measures in schizophrenia.
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Quality of life (QoL) is an important outcome in
schizophrenia research and was the primary outcome
of the UK CUtLASS trials (Cost Utility of the Latest
Antipsychotics in Severe Schizophrenia) [1-3]. Self- or
patient-rated measures of QoL in schizophrenia can be
viewed with suspicion by the clinician [4] due to the per-
ceived impact of depressive and psychotic symptoms, poor
insight, and cognitive deficits [5,6]. The alternative is
clinician- or assessor-rated measures of QoL but these
show only moderate correlation with self-ratings [7-9].
Existing literature converges on extensive differences
between the predictors of subjective and objective QoL.
Previous researchers have found, for example, with the
use of factor analysis, that subjective and objective QoL
components cluster separately [10]. The majority of stud-
ies have examined the predictors of patient-rated and
assessor-rated QoL separately, for example, research on* Correspondence: karen.hayhurst@manchester.ac.uk
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unless otherwise stated.outpatients with schizophrenia concluded that objective
and subjective QoL measures have different clinical pre-
dictors and should be considered separate outcomes
[11-13]. Similarly, a recent review highlighted that few
studies had investigated the relationship between subjective
and objective QoL assessment, concluding that researchers
ought to use both approaches as complementary outcome
measures in schizophrenia [14]. This message was re-
iterated by Awad and Voruganti in their 2012 update on
QoL measurement in schizophrenia [15].
Two major QoL measures used for schizophrenia are the
objective QLS (Quality of Life Scale) [16] and the LQOLP
(Lancashire Quality Of Life Profile) [17]. The QLS consists
of a series of questions regarding common social achieve-
ments (see Methods section). The LQOLP consists of a
series of questions including two visual analogue scales of
subjective life satisfaction (see Methods section).
It is not enough, however, to know that the two types of
measure differ. An important issue to examine is what
makes them differ. QoL measurement discrepancy serves
to highlight fundamental differences between the prioritiesal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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patient dissatisfaction with treatment. In addition, know-
ledge of the drivers of QoL discrepancy can inform re-
search using QoL as an outcome measure.
Despite a large QoL evidence base, few researchers
have specifically examined predictors of discrepancy be-
tween the two methods of QoL measurement in the
same individual. One such study did suggest that pa-
tients with QoL measurement concordance were more
likely to be young, male and have high symptom scores
[18]. Patient ratings in this study, however, were mea-
sured using a subjective measure of function; the Sub-
jective Well-being on Neuroleptics (SWN) scale [19],
rather than with a specific quality of life measure [18].
Other studies have employed specific QoL measures.
Poor insight was linked to greater discrepancy between
objective (Standard of Living Interview SOL-I) [20] and
subjective (LQOLP) [17] measures of QoL by Doyle and
colleagues [6]. Similarly, Whitty et al. [21] suggest that
better insight may serve to lower both subjective (WHO
Quality of Life Scale Brief Version) [22] and objective
QoL (QLS) [16]. A further study using the patient's global
QoL assessment and the interviewer's global QoL assess-
ment from the same measure; the LQOLP [17] highlighted
an association between greater QoL measurement discrep-
ancy and fewer affective symptoms [7].
During the UK CUtLASS trials [1-3] QoL of partici-
pants at one trial site was assessed using the patient-
rated LQOLP [17] in addition to the observer-assessed
QLS [16]. This provided the ideal opportunity to assess
in detail what factors affect each construct and (most
importantly) the discrepancy between the two.
Methods
Design
The study was conducted in parallel to the CUtLASS trials
[1-3], which comprised two randomised controlled trials
(RCTs) recruiting from five centres across the UK. The
first trial compared FGA (first generation antipsychotic)
drugs with non-clozapine SGAs (second generation anti-
psychotic). The second of the two trials compared SGA
drugs, as a class, with clozapine in treatment-resistant pa-
tients (poor response to two or more prior antipsychotics).
Participants
Individuals with DSM schizophrenia, schizoaffective dis-
order, or delusional disorder and aged 18–65 years, whose
treating clinicians were considering a change of anti-
psychotic due to lack of response, or intolerable side ef-
fects, were eligible for the study. The referring clinician
discussed the CUtLASS trials with the participant and sup-
plied them with an information sheet. The Trial Support
Clinician checked their eligibility from case notes, assigned
a study number and visited within 3 days to obtain writtenconsent [3]. Ethical approval was granted by the North
West Multi-Centre Research Ethics Committee.
Procedure and measures
Inclusion criteria for the first trial were at least one
month since the first onset of positive psychotic symp-
toms and psychiatrist electing to change current treatment
because of inadequate clinical response or intolerance [1].
Inclusion criteria for the second trial were the responsible
clinician electing to change current treatment because of
poor clinical response (and considering clozapine), plus tri-
als of at least two previous drugs, with poor clinical re-
sponse [2]. Exclusion criteria for both trials were substance
misuse or a medical disorder considered clinically to be the
major cause of positive psychotic symptoms and a history
of neuroleptic malignant syndrome [1,2]. This paper
reports baseline measures; assessments were carried
out by the Trial Support Clinician, a Specialist Registrar in
Psychiatry, i.e. ratings of observer-assessed QoL were not
made blind to other study ratings.
Participants were assessed using the Positive and Nega-
tive Syndrome Scale (PANSS) [23]; the Calgary Depression
Scale for Schizophrenia (CDSS) [24]; the Drug Attitude
Inventory (DAI) [25]; and the Kemp Adherence Scale [26].
The PANSS [23] is a well-validated measure of symp-
toms in schizophrenia, providing ratings on three sub-
scales (positive, negative and general psychopathology).
The CDSS [24] is widely used as a measure of depres-
sive symptoms in schizophrenia. The DAI [25] and
Kemp scale [26] measure attitudes and adherence to
treatment.
Treatment-related side effects were measured using
the Simpson-Angus scale [27]; the Barnes Akathisia scale
[28]; the Assessment of Involuntary Movements Scale
(AIMS) [29]; and the Antipsychotic Non-Neurological
Side Effects Rating Scale (ANNSERS) [30], a scale with
good inter-rater reliability [31] designed to measure adverse
events associated with both SGA and FGA treatment.
The primary outcome for the study was quality of life
measured on an observer-assessed measure: the Quality
of Life Scale (QLS) [16]. The QLS is the most widely
used QoL scale in the evaluation of psychopharmacolog-
ical treatments for schizophrenia [32]. The scale consists
of 21 items, with anchored ratings of 0–6, across four
domains: social relationships, instrumental role func-
tioning, intra-psychic foundations and activities of daily
life. The QLS is rated by trained raters, via a semi-
structured interview schedule (e.g. a suggested question
for social activity ratings is, "how often have you done
things for enjoyment that involve other people?"). It has
good inter-rater reliability and confirmatory factor analysis
has been carried out. The scale has been shown to be both
sensitive to change and of clinical relevance [33]. A meas-
ure of high internal consistency (Cronbach α 0.92) was
Table 1 Demographic and clinical characteristics of the
sample
Baseline variables (N = 80)
Gender, Male (%) 54 (68%)
Smoking, Yes (%) 61 (76%)
Current drug use, Yes (%) 23 (29%)
Current alcohol use, Yes (%) 23 (29%)
Mean (SD) Median Range
Age (yr) 39.8 (10.9) 40.1 18.5 - 60.1
Duration of Illness (yr) 13.16 (11.24) 9.04 0 - 38
Number of previous
hospitalisations
4.78 (5.89) 3.00 0 - 40
Patient-rated QoL
(LQOLP average)
3.95 (1.48) 3.50 1 – 7
Assessor-rated QoL
(QLS total score)
41.61 (17.55) 39.00 11 – 91
Insight (BIS) 12.15 (3.45) 12.00 2 – 16
Depression (CDSS) 9.04 (6.21) 8.00 0 – 22
Positive symptoms (PANSS) 16.89 (6.14) 16.00 7 – 32
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in the CUtLASS study and an inter-rater reliability of 0.99
(intra-class correlation: ICC) achieved for total QLS score;
an ICC of 0.84 was obtained for PANSS total score [1]. An
initial QLS ICC of 0.91 was obtained for 9 trained raters,
using 10 videotaped QLS assessments; further training
succeeded in raising the QLS ICC to 0.99 [1].
For the purposes of the current study, 80 participants at
the Manchester trial site also completed the widely-used,
patient-rated Lancashire Quality Of Life Profile (LQOLP)
[17] and the Birchwood Insight Scale (BIS) [34]. The
LQOLP was developed out of Lehman’s QoL scale [35]
and has both proven reliability [36] and validity [37].
The patient’s global assessment of their own subjective
QoL was used for the analysis, which is taken as the
average of responses to the general well-being question,
completed at the start and end of the LQOLP ("can you
tell me how you feel about your life as a whole") [6,38].
The BIS [34] is a widely used self-report measure of
insight.Negative symptoms (PANSS) 20.61 (5.49) 20.50 9 – 39
General psychopathology (PANSS) 40.33 (9.74) 40.50 22 - 64
Total symptom score (PANSS) 77.83 (17.44) 76.50 45 – 128
Adherence Rating (Kemp) 5.04 (1.44) 5.00 1 - 7
Drug Attitude (DAI) +11.08 (10.95) +10.00 −18 - +30
Simpson-Angus 4.64 (4.23) 4.00 0 – 22
Barnes Akathisia 3.63 (3.18) 3.50 0 – 11
AIMS 1.60 (2.59) 1.00 0 – 15
Non-neurological side effects
(ANNSERS)
19.37 (10.13) 20.00 1 – 39
Body Mass Index (BMI) 26.83 (6.33) 26.10 16.5 – 50Data analysis
Scores on each QoL measure were converted into z
scores, or standard scores (with a mean of zero and unit
variance), to allow for an analysis of the statistical deter-
minants of discrepancy between the two measures. Cor-
relations were calculated for z score difference between
subjective and objective measures (LQOLP minus QLS)
and baseline variables. Forwards multiple linear regres-
sion analyses of predictor variables (with p values of less
than 0.2) on patient-rated and assessor-rated QoL and on
QoL discrepancy (LQOLP minus QLS) were performed. A
p value of less than 0.2 was chosen as we did not wish to
exclude confounders with trend significance with the po-
tential to affect the relationship between the predictors of
interest and the outcome variable. Data were analysed
using SPSS for Windows, version 20.Results
Sample
Characteristics of the sample are set out in Table 1.
Most patients were male, the median duration of illness
was nine years and the sample had a median of three
previous hospitalisations.
At baseline assessment correlation between the two
measures of quality of life in those 80 participants with
scores on both QoL measures was r = 0.384 (p = 0.001).
Associations between patient-rated (LQOLP) and assessor-
rated (QLS) quality of life and baseline variables were exam-
ined (see Table 2).
In order to determine the factors associated with QoL
measurement discrepancy, we firstly examined predic-
tors of the LQOLP and the QLS, separately.Patient-rated quality of life
The following variables were entered into a forwards
multiple linear regression on the basis of a univariate re-
lationship with a p value of less than 0.2 (see Table 2);
gender, smoking status, insight (BIS), depression (CDSS),
general psychopathology score (PANSS), BMI, ANNSERS
score and adherence rating. Table 3 shows that patient-
rated (LQOLP) quality of life was statistically determined
by depression (CDSS), insight (BIS), non-neurological side
effect score (ANNSERS) and adherence rating (Kemp).
In the model, depression explains 34% of the vari-
ance in score on the LQOLP, insight a further 5.6%,
non-neurological side effects 4%, and adherence rating
a further 4.6% each. These four predictor variables taken
together therefore explain 48% of the variance in patient-
rated QoL. Increased depression, insight and rated adher-
ence are associated with decreased patient-rated QoL,
whereas increased ANNSERS score is associated with in-
creased patient-rated QoL.
Table 2 Univariate predictors of patient-rated and
assessor-rated quality of life
Patient-Rated
QoL (N = 80)
Assessor-Rated
QoL (N = 80)
Variable Mean p Mean p
Gender M = 3.78 0.176 M = 38.28 0.019
F = 4.27 F = 48.28
Smoking Yes = 3.84 0.198 Yes = 38.69 0.007
No = 4.38 No = 51.59
Current drug use Yes = 3.71 0.386 Yes = 37.29 0.185
No = 4.05 No = 43.30
Current alcohol use Yes = 3.63 0.301 Yes = 38.62 0.368
No = 4.02 No = 42.75
r p r p
Duration of illness (yr) 0.065 0.588 0.203 0.084
Number of previous
hospitalisations
−0.037 0.767 −0.123 0.313
Insight (BIS) −0.360 0.003 0.136 0.285
Depression (CDSS) −0.600 <0.001 −0.279 0.016
Positive symptoms
(PANSS)
0.011 0.928 −0.285 0.013
Negative symptoms
(PANSS)
−0.078 0.511 −0.676 <0.001
General psychopathology
(PANSS)
−0.298 0.010 −0.482 <0.000
Total symptom score
(PANSS)
−0.190 0.105 −0.590 <0.001
Body Mass Index (BMI) 0.160 0.190 0.180 0.139
Simpson-Angus −0.048 0.688 −0.066 0.575
Barnes Akathisia −0.133 0.267 −0.075 0.523
AIMS 0.099 0.410 0.076 0.521
Non-neurological side
effects (ANNSERS)
−0.254 0.030 −0.056 0.635
Adherence Rating (Kemp) −0.217 0.063 0.215 0.065
Drug Attitude (DAI) −0.145 0.222 0.422 <0.001
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Possible predictor variables were, again, entered into a
forwards multiple linear regression on the basis of a uni-
variate relationship with a p value of less than 0.2 (see
Table 2); gender, smoking status, current drug misuse,
duration of illness, depression (CDSS), positive symp-
toms (PANSS), negative symptoms (PANSS), general
psychopathology score (PANSS), BMI, adherence rating
and DAI score. Table 3 shows that assessor-rated (QLS)
quality of life was predicted by negative symptom score
(PANSS) and drug attitude rating (DAI). The main pre-
dictor, negative symptom score, explains 43% of the vari-
ance in Heinrich’s QLS. A one-point increase in PANSS
negative symptom subscale score is associated with a
substantial decrease in assessor-rated QoL of two points.DAI score explains a further 7.7% of the variance, with
these two variables together explaining 50% of the vari-
ance in assessor-rated QoL. Although significant correla-
tions were observed between adherence rating and DAI
score (r = 0.434, p < 0.001) and between PANSS subtotal
scores (PANSS positive with PANSS negative r = 0.222,
p < 0.05; PANSS positive with PANSS general r = 0.616,
p = <0.001; PANSS negative with PANSS general r =
0.496, p < 0.001) multi-collinearity was not present in
the dataset (tolerance of above 0.5 and VIF less than 2.0
for each predictor).
Factors associated with QoL measurement discrepancy
The following variables were entered into a forwards
multiple linear regression on the basis of a univariate re-
lationship with a p value of less than 0.2 (see Table 4);
gender, smoking status, insight (BIS), depression (CDSS),
positive symptom score (PANSS), negative symptom
score (PANSS), non-neurological side effect (ANNSERS)
score, adherence rating (Kemp) and drug attitude (DAI)
score. Table 3 shows that the final model contained
insight (BIS), negative symptom score (PANSS), depres-
sion (CDSS) and drug attitude (DAI) score. Insight explains
20% of the variance in QoL measurement discrepancy,
negative symptoms a further 9.7%, depression a further 9%
and drug attitude score a further 8.4%. Together these four
predictor variables therefore explain 48% of the variance in
measured quality of life discrepancy. Relative to objective
quality of life, subjective quality of life is scored lower in
the presence of greater insight, greater depression, greater
concordance and reduced symptoms.
Discussion
A significant but moderate correlation (r = 0.38) was found
between patient-rated and assessor-rated measures of QoL
in patients with schizophrenia (N = 80) participating in a
clinical trial. This confirms previous findings [7,8,39],
whilst pointing to the existence of differing constructs of
the concept of QoL on the part of the patient and the
assessor, or clinician. Separate analyses of the two QoL
measures allowed us to understand the drivers of the dis-
crepancy between the two; a previously under-researched
topic.
As in previous studies, for example, Narvaez et al.
[11], good insight and depression predicted low patient-
rated QoL [7,8,11,12,39-46] but not assessor-rated QoL,
driving the discrepancy between the two measures. Pre-
vious work has highlighted the relationship between
good insight and depression [47]. Increased insight will
serve to decrease the patient’s rating of their own QoL,
to bring it more in line with the rating given by an ob-
server, thereby reducing QoL measurement discrepancy.
Good insight could be toxic, in that it can erode self-
esteem and promote self-stigmatisation; but it may also
Table 4 Univariate predictors of quality of life
measurement discrepancy
Patient-rated minus
Assessor-rated QoL z score
Variable Mean p
Gender Male +0.21 0.117
Female −0.22
Smoking Yes +0.15 0.153
No −0.32
Current drug use Yes +0.21 0.494
No +0.00
Current alcohol use Yes +0.19 0.484
No −0.02
Variable r S
Length of illness (yr) −0.152 0.216
Number of previous hospitalisations 0.036 0.779
Insight (BIS) −0.452 <0.001
Depression (CDSS) −0.321 0.007
Positive symptoms (PANSS) 0.272 0.023
Negative symptoms (PANSS) 0.432 <0.001
General psychopathology (PANSS) 0.098 0.420
Total symptom score (PANSS) 0.293 0.014
BMI −0.067 0.595
Simpson-Angus 0.010 0.936
Barnes Akathisia −0.117 0.338
AIMS 0.034 0.782
ANNSERS −0.209 0.082
Adherence Rating (Kemp) −0.374 0.001
Drug Attitude (DAI) −0.483 <0.001
Table 3 Statistical determinants of quality of life and of measurement discrepancy
Model Predictors B SE Beta p 95% CI R square change F change Sig. F change
QoL discrepancy (patient-rated minus assessor-rated QoL z score)
Insight (BIS) −0.04 0.04 −0.14 0.243 −0.12 to 0.03 0.204 15.63 <0.001
Negative symptoms (PANSS) 0.09 0.02 0.39 <0.001 0.04 to 0.13 0.097 8.34 0.005
Depression (CDSS) −0.07 0.02 −0.39 <0.001 −0.11 to −0.03 0.090 8.75 0.004
Drug attitude (DAI) −0.04 0.01 −0.35 0.003 −0.06 to −0.01 0.084 9.31 0.003
Patient-rated quality of life
Depression (CDSS) −0.16 0.03 −0.68 <0.001 −0.22 to −0.10 0.339 30.26 <0.001
Insight (BIS) −0.09 0.04 −0.22 0.029 −0.17 to −0.01 0.056 5.39 0.024
Non-neurological side-effects (ANNSERS) 0.04 0.02 0.28 0.025 0.01 to 0.08 0.040 4.08 0.048
Adherence (Kemp) −0.24 0.11 −0.22 0.030 −0.45 to −0.02 0.046 4.93 0.030
Assessor-rated quality of life
Negative symptoms (PANSS) −2.00 0.33 −0.57 <0.001 −2.65 to −1.35 0.427 48.48 <0.001
Drug attitude (DAI) 0.46 0.15 0.29 0.003 0.17 to 0.75 0.077 9.89 0.003
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course, rating one’s quality of life as worse is not the
same as experiencing a life of poorer quality.
Although QLS and subjective QoL global ratings were
correlated, this could conceal substantial variation in the
relationship between different aspects of objective QoL
and satisfaction. Edmondson and colleagues [50] discov-
ered this when comparing change in various measures of
social functioning and satisfaction with them. They argued
that this could be explained by Zissi and Barry’s [51] sug-
gestion of a shift in aspirations as function improves.
Negative attitudes to medication, as measured by DAI,
predicted lower objective QoL but not self-rated QoL,
increasing the discrepancy. Negative attitude toward pre-
scribed treatment is associated by the observer with re-
duced QoL in a way that patients do not perceive.
Good adherence (based on openly expressed attitudes
and medication-related behaviour) predicted low con-
current patient-rated QoL but not assessor-rated QoL
nor QoL measurement discrepancy. Other research has
suggested that direct links between adherence and QoL
are weak or absent [52,53], although this pattern was ob-
served using self-report, rather than externally-assessed,
adherence. This type of study is not designed to address
the meaning of adherence to individuals and hence
understand how it affects QoL [54]. One possibility is
that good adherence, if it does not spring from positive
attitudes to treatment and a sense of self-efficacy, reflects
a sense of burden by illness or services. Positive attitude
to medication (rather than broader service relationships)
against a complex background of emotive attitudes to ser-
vices and illness might not be enough.
As in previous studies, greater negative symptomatology
predicted lower assessor-rated QoL [5,6,8,11-13,39,40,55]
but not patient-rated QoL, suggesting that to a clinician,
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the prime driver of quality of life. This corresponds with
previous survey research indicating that psychiatrists’ con-
cept of QoL is more illness-orientated [56]. Negative
symptoms may have little subjective impact on the patient,
whereas they are apparent to an observer, or assessor [8].
Others have argued that negative symptoms linked to the
deficit syndrome in schizophrenia can serve to protect the
individual's self-esteem via social withdrawal [57], al-
though this perspective would suggest that there ought to
be a relationship between negative symptoms and subject-
ive QoL, which was not found here. QLS score is influ-
enced by social function, which is linked to negative
symptoms. Hence, negative symptoms will impair one
form of QoL measurement without affecting the other;
enhancing the discrepancy.
Increased experience of non-neurological side effects
was predictive of higher self-reported QoL but of neither
assessor-rated QoL nor the discrepancy. Patients with a
higher QoL rating may report side effects as more se-
vere; these experiences may have a greater impact on the
lives of better-functioning individuals. This relationship
was only observed for non-neurological side effect scores,
not extrapyramidal side effects (EPS); others have found
an association between patient-rated QoL and EPS [58]. A
significant positive correlation between ANNSERS score
and depression score suggests the experience of non-
neurological treatment side effects contributes to depres-
sive symptoms.
The study had a number of limitations. Data were col-
lected during baseline assessments of a RCT; the cross-
sectional design therefore means that assumptions of
causality in the statistical models must be viewed with
caution. In addition, the sample analysed here was com-
prised of patients entered into a RCT, because of poor
clinical response or intolerance, although the trial did
have broad inclusion criteria. Although conclusions were
derived from a relatively small sample (N = 80) QoL pre-
dictive factors highlighted by this study are consistent
with the existing evidence base.
In terms of measures used, a number of variables found
to be associated with QoL in previous studies, for ex-
ample, neurocognitive deficits, social support, coping style
and anxiety, were not assessed in this sample. It is not
known whether the statistical determinants of QoL meas-
urement discrepancy observed here will apply to discrep-
ancies between other patient- and assessor-rated QoL
measures. Analysis did include demographic variables pre-
viously associated with QoL, such as gender, although
other demographic data, which may also be associated
with QoL, such as social class and educational level, were
not available. In terms of the possible effects of medica-
tion, the main outcome paper of the CUtLASS study re-
ported no significant effect of antipsychotic drug class onQoL [1]. The CUtLASS study used a depression scale de-
veloped for use specifically in schizophrenia and used
measures of QoL with proven reliability and validity. The
QLS is argued to be largely determined by the deficit
symptoms of schizophrenia [59] leading to the strong rela-
tionship between the QLS and negative symptoms re-
ported in previous studies [60]. Potentially, the QLS and
negative syndrome overlap, as both are reflective of poor
social function. However, we found that items for anhedo-
nia, alogia and blunting were, though conceptually dis-
tinct, as predictive of the QLS score.
Conclusions
Our primary aim was to examine predictors of discrep-
ancy between two widely-used patient-rated and assessor-
rated quality of life measures in schizophrenia. There was
only moderate correlation between them and their predic-
tors differed. Patient-rated QoL appears mainly to reflect
depression, whilst assessor-measured QoL reflects nega-
tive symptoms. The largest single predictor of QoL meas-
urement discrepancy is insight. This explains 20% of its
variance (with less insight associated with better subjective
but not objective QoL) but its relationship may be medi-
ated by depression and medication concordance so it is
not a significant predictor in a multivariate model. Greater
negative symptoms predict discrepancy as high scores pre-
dict low objective but not subjective ratings of quality of
life.
These findings have relevance to both the clinical and
the research setting. In terms of practical management,
it appears that the alleviation of depressive symptoms ra-
ther than the alleviation of negative symptomatology is
more likely to lead to the patient rating their quality of
life as improved. For studies using QoL as the primary
outcome measure it is worth bearing in mind that the
inclusion of patients with low insight scores, low depres-
sion scores and high negative symptom scores will serve
to increase the degree of discrepancy between patient-
rated and assessor-rated QoL.
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